Howard Bailey Securities LLC Raises Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Howard Bailey Securities LLC raised its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 22.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,094 shares of the company’s stock after buying an additional 198 shares during the quarter. Howard Bailey Securities LLC’s holdings in IDEXX Laboratories were worth $452,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. FSA Wealth Management LLC purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. boosted its holdings in shares of IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after purchasing an additional 57 shares in the last quarter. Retirement Wealth Solutions LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter valued at about $31,000. Mowery & Schoenfeld Wealth Management LLC raised its holdings in shares of IDEXX Laboratories by 750.0% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock valued at $34,000 after buying an additional 60 shares in the last quarter. Finally, Ashton Thomas Securities LLC bought a new stake in IDEXX Laboratories in the 3rd quarter worth approximately $37,000. 87.84% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Sophie V. Vandebroek sold 344 shares of the business’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the sale, the director now owns 905 shares in the company, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 13,330 shares of company stock worth $6,161,276. 2.11% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of recent research reports. Leerink Partners assumed coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target on the stock. Barclays increased their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Piper Sandler upped their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, February 5th. Finally, Morgan Stanley lowered their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $533.75.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $457.35 on Thursday. The firm has a market cap of $37.45 billion, a P/E ratio of 42.86, a P/E/G ratio of 3.47 and a beta of 1.37. The business’s 50 day moving average price is $429.67 and its 200-day moving average price is $453.23. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $583.39. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.03 and a current ratio of 1.31.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.